Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some patients with non-small cell lung cancer (NSCLC), the most common type of lung ...
More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results